A Melbourne-based medical biotech, backed by RMIT University ... iStock Street Talk understands NEXSEN is seeking to raise $2 ...

We recently compiled a list of the 10 Best Up and Coming Stocks To Buy According to Analysts. In this article, we are going ...

HanX Biopharmaceuticals is planning a Hong Kong listing to fund the phase 2 trial of its lead solid tumor drug. | HanX ...

After a slow first quarter, biotech IPOs may finally start to come into vogue in the coming months as a series of companies announced plans to go public. Market watchers had expected a busy first ...

After a decade of significant challenges, biotech's long-term sustainability depends on making fundamental changes to its traditional business model. A commonly held perception in the biotech ...

Biotech IPOs are making a comeback alongside the sector’s recent gains as funding constraints fueled by record-high interest ...

Legend Biotech is spinning out from parent firm GenScript Biotech to pursue treatments in CAR T cell therapies for multiple myeloma. Legend Biotech is spinning out from parent firm GenScript ...

Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and ...

Biotech investors will ... HaemaLogiX’s preliminary view is that it will raise $50m as part of next year’s IPO. HaemaLogiX, in its current form, has so far raised $24.1m.

Going public with a valuation higher than $300 million may now be necessary to attract interest from institutional investors. A few times over the past two decades, a confluence of forces has ...

In this article, we are going to take a look at where Legend Biotech Corp. (NASDAQ ... companies that have been hesitant to pursue IPOs in 2025, capitalizing on the positive market reaction ...